This presentation was developed for trainings in a country that adopted DTG 50mg singles. Please note that now a fixed-dose combination of TLD is available, some recommendations included in this presentation may not be relevant where TLD is in use instead of DTG single. Countries can use this presentation for trainings, but content should be modified and adapted for the local context factoring in local HIV guidelines, clinical practices, data systems, and rollout strategies.
Comments